Home Stakeholders Health & Social Care Stakeholders Global Kinetics – Parkinson’s disease management

Global Kinetics – Parkinson’s disease management

Global Kinetics aim to improve the lives of those with Parkinson’s disease with advanced medical technologies

Global Kinetics Pty Ltd. is committed to improving the lives of those with Parkinson’s disease with advanced medical technologies. The company was formed in 2007 to commercialize its lead product, the Personal KinetiGraph® (PKG®). The PKG enables the precise monitoring, quantification, and reporting of movement symptoms in Parkinson’s. To date, Global Kinetics has supported clinical decisions for doctors who have treated more than 30,000 patients with Parkinson’s disease, generating more than 7,200,000 hours of clinical data from the FDA-cleared, CE-marked PKG wearable system.

The Personal KinetiGraph system (PKG)

The company’s Personal KinetiGraph system (PKG) is a patient-friendly, algorithm-based system that records patients’ movements over the course of several days and creates data-driven reports that empowers more personalised treatment and management decisions—ultimately leading to a higher quality of life for patients.

The algorithms are all clinically validated and correlated to the standard Parkinson’s assessment tools such as the Unified Parkinson’s Disease Rating Scale (UDPRS), Abnormal Involuntary Movement scale AIMs and the sleep scales including the Epworth Sleep Scale (ESS) and polysomnography.

The PKG Service

The PKG service includes the PKG Watch, a wrist worn device that records symptoms that can be programmed to remind a patient when to take their Parkinson’s disease medication, as prescribed by a clinician, fulfillment of the PKG kit directly to the patient’s home and a clinician portal to view a detailed PKG report. The PKG recording is carried out at home over a 6-day period, whilst the patient performs normal activities.

Clinical Application of the PKG

The PKG report and can provide a healthcare professional (HCP)  with useful and actionable insights and should be used as an adjunct to their clinical assessment both in an in office and / or remote patient management setting. The report provides insight over a 24-hour period and provides:

  • An assessment of bradykinesia, (slowness)
  • Dyskinesia (excessive abnormal movement)
  • Tremor
  • Immobility and inactivity over the 24 hours, providing insight into sleep and restlessness
  • A correlation of symptom fluctuations and their severity with respect to levodopa dosage
  • The patient’s self-reported levodopa compliance

The PKG report is a complementary tool for HCPs. It provides objective insight when there is uncertainty of what the patient describes and a reality of how the patient is in an ambulatory environment. The HCP and patient can make joint decisions about the type and amount of medication and obtain a longitudinal view of the patient’s symptoms. For the healthcare system there are efficiencies to be gained via more accurate insight at the time of consultation and via remote patient management care pathways.

Current Customers

National Health Service, (NHS) UK. Public Hospitals in Nordics & Netherlands, Air Liquide (Orkyn), France, US academic and community-based clinics (USA)

Summary of Clinical Evidence

The PKG has led to improved clinical utility and over 80% of time uncovers intervention opportunities and influences changes in the treatment plan for people with Parkinson’s. In one 200-patient controlled study, there was a reported 8.5-point difference in MDS-UPDRS total score when patient treatment included the PKG vs. a 4.9-point difference in the standard of care arm (p=0.001).1 This demonstrates both a statistical and clinically important difference when the PKG is used to guide therapeutic treatment such as indicated medication titration.  In addition, it has been documented that 59% of clinicians reported an improvement in dialogue and engagement around Parkinson’s symptoms and patient surveys have indicated that the PKG was easy to use (93%), performed as expected (96%) and would use again (100%).2-3  Whilst the clinical evidence for the PKG remains sound, it is also important to note the economic value of the PKG. A recent study demonstrated that the PKG has also been shown to be cost effective in the NHS, when including the social costs of uncontrolled Parkinsons symptoms.4  In the future studies will show the impact of the PKG on patients’ self-management.

NICE have recently  issued NICE Guidance and the PKG has conditional recommendation.


1 Woodrow H, Horne M, Fernando C, Kotschet K and Treat to Target Study Group. A blinded, controlled trial of objective measurement in Parkinson’s disease. npj Parkinson’s Disease (2020) 6:35 ; https://doi.org/10.1038/s41531-020-00136-9
2 Joshi R, Bronstein JM, Alcazar J, Yang D, Joshi M, Hermanowicz N. An Observational Study of PKG Movement Recording System Use in Routine Clinical Care of Patients with Parkinson’s Disease. Movement Disorders Front. Neurol., 01 October 2019 | https://doi.org/10.3389/fneur.2019.01027
3 Nahab FB, Abu-Hussain H, Moreno L. (2019) Evaluation of Clinical Utility of the Personal KinetiGraph in the Management of Parkinson’s Disease. Advances in Parkinson’s Disease, 8, 42-61. https://doi.org/10.4236/apd.2019.83005



Stakeholder Profiles